Navigation Links
Alpine Biomed Corporation to Integrate Bravo pH Monitoring With GastroTrac Software to Enhance Gastrodiagnostic Testing Capabilities
Date:5/15/2009

Company Signs Agreement with Given Imaging Ltd. to Offer Customers Integrated Testing Solution

FOUNTAIN VALLEY, Calif., May 15 /PRNewswire/ -- Alpine Biomed Corporation, a global leader in specialty diagnostic devices, announced today that it has signed an agreement with Given Imaging Ltd. to enhance its gastrodiagnostic testing capabilities. The company's GastroTrac(R) gastroenterology software suite will interface with Given Imaging's Bravo(R) pH Monitoring System to provide doctors with a single system for their gastrointestinal testing needs.

Alpine Biomed will incorporate the Bravo pH software into a fully integrated version of GastroTrac with a comprehensive range of tests including catheter-based pH monitoring, upper and lower GI motility testing, electrogastrography and biofeedback. To simplify patient records, the Bravo pH software will share the GastroTrac database with the catheter-based pH monitoring studies. Alpine Biomed's VersaFlex(R) pH catheters and the Bravo pH capsule are the only pH devices validated for use on the integrated GastroTrac system.

"We are pleased to offer our customers a single solution for their gastrodiagnostic testing needs. This agreement will significantly benefit both our current and new customers. We look forward to working with our customers to implement an integrated solution that will better serve their practices," said Alpine Biomed President and CEO John Arnott.

Alpine Biomed is exhibiting at the Society for Gastroenterology Nurses and Associates Annual Course in St. Louis, May 17-19 (booth 737) and at the Digestive Disease Week meeting in Chicago May 31- June 3 (booth 1801).

About Alpine Biomed

Alpine Biomed is a global leader in specialty diagnostic devices for the gastroenterology and neurology clinical markets. The company produces diagnostic tools used for gastroesophageal reflux disease (GERD), co
'/>"/>

SOURCE Alpine Biomed Corporation
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market
2. BioMed Realty Trust Prices Public Offering of 16,000,000 Shares of Common Stock
3. BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock
4. Response Biomedical Announces Proposed Unit Offering
5. BioMed Realty Trust Reports First Quarter 2009 Operating and Financial Results
6. Dr. Abbott J. Krieger Joins Avery Biomedical Devices, Inc. as Chief Clinical Liaison
7. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
8. Four legendary LA BioMed physician-researchers honored
9. Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
10. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
11. BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivans Product Innovation of the Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2AMA Grants New Category III CPT Code to Premier Hearts Multifunction CardioGram 28TM 29 28MCG 29 51426 1AMA Grants New Category III CPT Code to Premier Hearts Multifunction CardioGram 28TM 29 28MCG 29 51426 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 1Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 2Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class 4717 3PR Whiz Belinda Foster Launches Michael Jacksons Nurse Cherilyn Lee on World Media Campaign 51425 1PR Whiz Belinda Foster Launches Michael Jacksons Nurse Cherilyn Lee on World Media Campaign 51425 2
Other Medicine Technology:Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 2Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 3Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10